SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

XACDURO

INVA·Innoviva, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US since May 2023.
Why 4/10
XACDURO was approved by the FDA on May 23, 2023, and is now a marketed, commercial-stage product with no pending regulatory decision or pivotal readout scheduled in the next 12 months. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Actionable Insight NEUTRAL

XACDURO is already approved and commercializing, so there is no single binary catalyst ahead. Watch quarterly IST product sales growth (Innoviva guided to at least $150M in total IST US net product sales for 2026) and any updates on the Dr. Reddy's international licensing deal. The stock trades near its 52-week low with a mean analyst price target of $35, implying significant upside if the commercial ramp continues, but the Q3 net loss of $73.9M from investment fair-value changes introduces headline risk.

Price Chart

Loading chart...

Executive Summary

XACDURO (sulbactam/durlobactam) is an FDA-approved intravenous antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Approved in May 2023, it is the first and only pathogen-targeted therapy for this difficult-to-treat superbug. Developed by Entasis Therapeutics (now part of Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., NASDAQ: INVA), XACDURO generated $33.4 million in US net sales in FY2025 and $16.1 million in Q3 2026, with the broader IST platform on track for at least $150 million in full-year 2026 US product sales. A June 2026 licensing deal with Dr. Reddy's expands international reach. XACDURO is a commercial-stage product with no pending regulatory binary, making it a steady but not explosive contributor to Innoviva's diversified revenue base, which also includes a large GSK royalty stream and other critical-care products.

How It Works

XACDURO is a co-packaged intravenous antibiotic that combines two drugs: sulbactam (which kills Acinetobacter bacteria by blocking cell-wall construction) and durlobactam (which protects sulbactam from being broken down by bacterial resistance enzymes). It is designed specifically to treat hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii, a notoriously hard-to-treat "superbug" that is a growing problem in hospitals.

Trial Status

XACDURO was approved by the FDA on May 23, 2023, based on the Phase 3 ATTACK trial, which demonstrated non-inferiority to colistin on 28-day all-cause mortality with higher clinical cure rates in patients with serious Acinetobacter infections, including carbapenem-resistant strains.

The Two-Sided Case

▲ Bull Case5
XACDURO is the first and only FDA-approved pathogen-targeted antibiotic for Acinetobacter, a serious multidrug-resistant hospital infection with high unmet need.
Q3 2026 XACDURO US net sales reached $16.1M, contributing to IST's 45% year-over-year growth, with full-year 2026 IST guidance of at least $150M in US net product sales.
The June 2026 Dr. Reddy's licensing deal extends XACDURO into South/Central America, the Caribbean, Russia and other international markets with upfront and milestone payments.
Analyst consensus shows 9 buy/strong-buy ratings vs. 1 hold and 1 sell, with a mean price target of $35 (roughly 83% above the current ~$19 stock price).
Innoviva's GSK royalty stream ($58.1M in Q3 2026) provides stable cash flow to fund commercial expansion and a $125M share buyback program.
▼ Bear Case4
XACDURO addresses a niche, multidrug-resistant Acinetobacter pneumonia market valued at roughly $350-530M globally, capping peak sales potential.
Innoviva swung to a $73.9M net loss in Q3 2026, driven by unfavorable changes in investment fair values, adding headline risk.
Several large institutional holders trimmed or exited INVA in Q2/Q3 2026, including Arrowstreet Capital (near-exit, -82%), Man Group (exit, -100%), and JPMorgan (trim, -59%).
The stock trades near its 52-week low of $19, and analyst coverage is stale (last action August 2026), suggesting limited near-term catalysts.

Upcoming Catalysts

  • Quarterly IST product sales reports and progress toward the 2026 guidance of at least $150M in US net product sales
  • Potential updates on Dr. Reddy's international commercialization milestones for XACDURO in licensed territories
  • Possible label expansion or pediatric study updates (though none currently scheduled)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Innoviva, Inc. 8-K INVA ·Originating report

Sources · 11

Hover a chip for the title
1 fda.gov2 accessdata.fda.gov3 en.wikipedia.org4 biospace.com5 tradingview.com6 businesswire.com7 nasdaq.com8 fortunebusinessinsights.com9 sec.gov10 investor.inva.com11 innovivaspecialtytherapeutics.com